https://orcid.org/0000-0002-3070-2949
Abstract
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
References
1.
Wang
L
, Gao
Z
, Chen
XP
, et al. Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis
. Sci Rep
. 2016
;6
:39003
.2.
Ghanima
W
, Cooper
N
, Rodeghiero
F
, Godeau
B
, Bussel
JB
. Thrombopoietin receptor agonists: ten years later
. Haematologica
. 2019
;104
(6
):1112
-1123
.3.
Ghadaki
B
, Nazi
I
, Kelton
JG
, Arnold
DM
. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
. Transfusion (Paris)
. 2013
;53
(11
):2807
-2812
.4.
Mahévas
M
, Fain
O
, Ebbo
M
, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study
. Br J Haematol
. 2014
;165
(6
):865
-869
.5.
Červinek
L
, Mayer
J
, Doubek
M
. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults
. Int J Hematol
. 2015
;102
(1
):7
-11
.6.
González-López
TJ
, Pascual
C
, Álvarez-Román
MT
, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
. Am J Hematol
. 2015
;90
(3
):E40
-E43
.7.
Newland
A
, Godeau
B
, Priego
V
, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
. Br J Haematol
. 2016
;172
(2
):262
-273
.8.
Lucchini
E
, Palandri
F
, Volpetti
S
, et al; for Gruppo Italiano Malattie Ematologiche dell’Adulto GIMEMA
. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study
. Br J Haematol
. 2021
;193
(2
):386
-396
.9.
Kapur
R
, Aslam
R
, Speck
ER
, Rebetz
JM
, Semple
JW
. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)
. Platelets
. 2020
;31
(3
):399
-402
.10.
Bao
W
, Bussel
JB
, Heck
S
, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents
. Blood
. 2010
;116
(22
):4639
-4645
.11.
Guillet
S
, Crickx
E
, Azzaoui
I
, et al. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
. Blood
. 2023
;141
(23
):2867
-2877
.12.
Carpenedo
M
, Cantoni
S
, Coccini
V
, Fedele
M
, Morra
E
, Pogliani
EM
. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice
. Hematol Rep
. 2015
;7
(1
):5673
.13.
Zufferey
A
, Speck
ER
, Machlus
KR
, et al. Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets
. Blood Adv
. 2017
;1
(20
):1773
-1785
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal